Segarra Medrano A, Vila Presas J, Pou Clavé L, Majó Masferrer J, Camps Doménech J. Efficacy

Segarra Medrano A, Vila Presas J, Pou Clavé L, Majó Masferrer J, Camps Doménech J. Efficacy and safety of combined cyclosporin A and mycophenolatemofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis. Nefrologia. 2011;31(3):286-91

Alfons.Segarra MD , Manuel Praga MD , Natalia Ramos MD, Natalia Polanco, 1,Isabel Cargol MD, Elena Gutierrez-Solis MD , Mª Rosa Gomez MD, Bruno Montoro MD , and Joaquim .Camps MD Successful Treatment With Rituximab Of Membranous Glomerulonephritis With Dependence Of Calcineurin Inhibitors’ Clin J Am Soc Nephrol 4: 1083-1088, 2009

Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, Egido J, Praga M; Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009 Aug;4(8):1317-23.

Segarra-Medrano A, Jatem-Escalante E, Agraz-Pamplona I, Carnicer-Cáceres C,Ramos-Terrades N, Ostos-Roldán E, Quiles-Pérez MT, Arbós-Via MA . Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistanceto corticosteroids and calcineurin inhibitors. Nefrologia. 2013;33:448-61.

Segarra Medrano A, Romero Jaller K. The current evidence supporting rituximab treatment in primary glomerular diseases causing nephrotic syndrome: Critical review. OA Nephrology 2013 Apr 01;1(1):3.

Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH. CD80 and suPAR in patients with minimal change disease and focalsegmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol. 2014 Aug;29(8):1363-71.

Segarra-Medrano A, Jatem-Escalante E, Quiles-Pérez MT, Salcedo MT, Arbós-ViaMA, Ostos H, Valtierra N, Carnicer-Cáceres C, Agraz-Pamplona I. Prevalence,diagnostic value and clinical characteristics associated with the presence ofcirculating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. Nefrologia. 2014 May 21;34(3):353-9.

Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, CarnicerC,Salcedo MT. Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis. Nefrologia. 2014 Jan 24;34(1):53-61.

Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, Carnicer C,Agraz I, Salcedo MT. Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome. Nefrologia. 2014 Jan 24;34(1):46-52.

Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, Agraz-Pamplona I,Salcedo MT, Valtierra N, Ostos-Roldán E, Arredondo KV, Jaramillo J. Evolution of antibodytitre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia. 2014;34 (4):491-7.

Caro J, Gutiérrez-Solís E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C, Espinosa M, Valera A, Martín M, Frutos MA, Perea L, Juárez GF, Ocaña J, Arroyo D, Goicoechea M, Fernández L, Oliet A, Hernández Y, Romera A, Segarra A, Praga M;forthe Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant.2014 Oct 1.pii: gfu306. [Epub ahead of print] PubMed PMID: 25274748.

SegarraMedrano AS, Escalante EJ, Cáceres CC, Pamplona IA, Allende MT, Terrades NR, Carmeno NV, Roldán EO, Agudelo KV, Vasquez JJ. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Biomarkers. 2015 Feb;20(1):77-83.

Jatem Escalante E, Segarra Medrano A, CarnicerCáceres C, Martín-Gómez MA,Salcedo Allende MT, OstosRoldan H, Agraz Pamplona I. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor. Nefrologia.2015 Jul 7.pii: S0211-6995(15)00063-6. doi: 10.1016/j.nefro.2015.05.026. [Epub ahead of print]English, Spanish. PubMed PMID: 26306972.